18 results
S-3
EX-1.2
BOLT
Bolt Biotherapeutics Inc
30 Mar 22
Shelf registration
5:14pm
, in accordance with the provisions of Section 11 hereunder, will pay the following expenses all incident to the performance of its obligations hereunder
10-K
2020 FY
BOLT
Bolt Biotherapeutics Inc
31 Mar 21
Annual report
4:06pm
cohort. These dose levels were well tolerated by all four patients and they completed the safety evaluation period without incident. Neither dose
424B4
BOLT
Bolt Biotherapeutics Inc
5 Feb 21
Prospectus supplement with pricing info
4:44pm
were well tolerated by all four patients and they completed the safety evaluation period without incident. Neither dose was expected
S-1/A
8072ga7ulyq5vjvx 7u6
1 Feb 21
IPO registration (amended)
6:24am
S-1/A
EX-1.1
mfgc3hrfsxwd
1 Feb 21
IPO registration (amended)
6:24am
S-1
EX-3.4
qi6xn mct
15 Jan 21
IPO registration
3:58pm
S-1
EX-10.19
izx3hig
15 Jan 21
IPO registration
3:58pm
S-1
EX-3.3
t1kwjfuibv mu5w0c90
15 Jan 21
IPO registration
3:58pm
S-1
EX-10.17
ti1h17i9w3ip734il5o
15 Jan 21
IPO registration
3:58pm
S-1
EX-10.18
umokn3x
15 Jan 21
IPO registration
3:58pm
S-1
bm2 vxagz
15 Jan 21
IPO registration
3:58pm
DRS/A
EX-10.19
8of522a5 ap
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.17
m490fjmq8sso83do
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.18
otn7kkzmle8mf5
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
EX-3.3
ispt3mac
11 Sep 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next